

Level 14, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand

> Phone 64-4-460-4990 Fax 64-4-460-4995

Please note – a word document of this document (rather than a PDF) is available from Jessica@pharmac.govt.nz upon request.

www.pharmac.govt.nz

Schedule 4: Proposal form

You should expand the boxes as necessary.

[Supplier to insert date]

Stephen Woodruffe
Therapeutic Group Manager
PHARMAC
PO Box 10-254
(or for courier delivery:
Level 14, Cigna House
40 Mercer Street)
Wellington
New Zealand

By facsimile (04) 460 4995

By email: stephen.woodruffe@pharmac.govt.nz

Dear Stephen

Proposal for the supply of quinapril and/or quinapril with hydrochlorothiazide

In response to your request for proposals (RFP) dated 18 June 2008, we put forward the following proposal in respect of [insert pharmaceutical(s)].

Set out below is further information in support of our proposal.

(a) Our contact details:

Name of supplier	
Contact person	
Address	
Phone	
Facsimile	
Email address	

(b) Details of pharmaceutical presentation:

Chemical name	
---------------	--

Strength (e.g. 5mg)			
Form (e.g. tablet)			
Brand name			
Pack size (e.g. 30's)			
Packaging type (e.g. blister)			
Key features of our proposal:			
Information relating to pricing conditions or proposed terms affe	including	any	related

Evidence of market approval and any other required consents:

Date of market approval (please attach copy of

OR Date of submission of dossier (please attach confirmation from Medsafe that dossier

OR Expected date of dossier submission to

Insert any other consents required for

Medsafe Gazette notice)

has been submitted)

Medsafe

pharmaceutical

(e)

A206085 - qA11136

Information	about our	previous	s supply	y perforn	nance	and relev	ant e	xpertise:
Proposals/s RFP that we	uggestions would like	s regard e PHAR	ing the MAC to	pharma conside	ceutica er as p	al not exp art of our	ressly propo	[,] identifie osal:
Reasons wh	ny PHARM	IAC sho	uld acc	ept our p	oropos	al:		
	,				•			

A206085 - qA11136

(j)	Additional proposal:	information	that	PHARMAC	should	consider	when	evaluating	our

(k) Samples of the pharmaceuticals included in this proposal have been forwarded to PHARMAC (delete as appropriate): Yes/No

A206085 - qA11136 4